16. The composition of any one of claims 1 to 15, wherein the composition is in the form of an eye drop, suspension, gel, ointment, injectable solution, or spray.

17. ~~A method of treating presbyopia in a subject, comprising administering to the subject a therapeutically effective amount~~ Use of a composition according to any one of claims 1 to 16 in the manufacture of a medicament for treating presbyopia in a subject.

18. ~~A method of treating mild hyperopia in a subject, comprising administering to the subject a therapeutically effective amount~~ Use of a composition according to any one of claims 1 to 16 in the manufacture of a medicament for treating mild hyperopia in a subject.

19. ~~A method of treating irregular astigmatism in a subject, comprising administering to the subject a therapeutically effective amount~~ Use of a composition according to any one of claims 1 to 16 in the manufacture of a medicament for treating irregular astigmatism in a subject.

20. ~~A method of treating hyperopic accommodative esotropia in a subject, comprising administering to the subject a therapeutically effective amount~~ Use of a composition according to any one of claims 1 to 16 in the manufacture of a medicament for treating hyperopic accommodative esotropia in a subject.

21. ~~A method of treating glaucoma in a subject, comprising administering to the subject a therapeutically effective amount~~ Use of a composition according to any one of claims 1 to 16 in the manufacture of a medicament for treating glaucoma in a subject.

22. ~~A method of potentiating or enhancing interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues, in a subject, comprising administering to the subject a therapeutically effective amount~~ Use of a composition according to any one of claims 1 to 16 in the manufacture of a medicament for potentiating or enhancing interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues, in a subject.

23. The ~~method~~ use of any one of claims 17 to 22, wherein ~~administering comprises administering~~ the ~~composition~~ medicament is to be administered to an eye of the subject.

24. The ~~method~~ use of claim 23, wherein the ~~composition~~ medicament is to be administered to only one eye of the subject.

25. The ~~method~~ use of any one of claims 17 to 24, wherein the ~~composition~~ medicament increases refractive power of an eye of the subject by up to about 4.0 diopters.

26. The ~~method~~ use of any one of claims 17 to 25, wherein the subject is human.

27. ~~A method of treating an ocular condition in a subject, comprising administering to the subject a therapeutically effective amount~~ Use of a composition according to any one of claims 1 to 16 in the manufacture of a medicament for treating an ocular condition in a subject.

28. The ~~method~~ use of claim 27 wherein the ocular condition comprises presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, or glaucoma.

29. The ~~method~~ use of claim 27 wherein the ocular condition could alternatively be corrected with eye glasses having about +0.5D to about +1.0D lenses and wherein the therapeutically effective amount comprises from about 0.3% to about 1.0% pilocarpine.

30. The ~~method~~ use of claim 27 wherein the ocular condition could alternatively be corrected with eye glasses having about +1.0D to about +1.5D lenses and wherein the therapeutically effective amount comprises from about 0.8% to about 1.6% pilocarpine.

31. The ~~method~~ use of claim 27 wherein the ocular condition could alternatively be corrected with eye glasses having about +1.5D to about +2.0D lenses and wherein the therapeutically effective amount comprises from about 1.4 % to about 2.2% pilocarpine.